Fragment 1-13 of human and mouse GSK-3β sequence. Potentially useful as a competitive inhibitor of GSK-3β (Ser9) phosphorylation. Control peptide TCS 184 available (Cat. No. 2320).
(Modifications: Ser-13 = C-terminal amide)
|Storage||Desiccate at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solubility||Soluble to 1 mg/ml in water|
Preparing Stock Solutions
The following data is based on the product molecular weight 1425.58. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||0.7 mL||3.51 mL||7.01 mL|
|5 mM||0.14 mL||0.7 mL||1.4 mL|
|10 mM||0.07 mL||0.35 mL||0.7 mL|
|50 mM||0.01 mL||0.07 mL||0.14 mL|
References are publications that support the products' biological activity.
Peineau et al (2007) GSK3β mediates a novel interaction between LTP and LTD in the hippocampus. Neuron 53 703 PMID: 17329210
If you know of a relevant reference for TCS 183, please let us know.
View Related Products by Target
Keywords: TCS 183, supplier, Fragment, 1-13, GSK-3β, GSK-3beta, sequence, Glycogen, Synthase, Kinases, 3, Carbohydrate, Metabolism, TCS183, Glycogen, Synthase, Kinase, 3, Glycogen, Synthase, Kinase, Glycogen, Synthase, Kinase, 3, Tocris Bioscience
1 Citation for TCS 183
Citations are publications that use Tocris products. Selected citations for TCS 183 include:
Peineau et al (2007) LTP inhibits LTD in the hippocampus via regulation of GSK3beta. Neuron 53 703 PMID: 17329210
Do you know of a great paper that uses TCS 183 from Tocris? If so please let us know.
TCS 183 Reviews
Average Rating:(Based on 0 Reviews)
Literature in this Area
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.